Hepatocellular carcinoma
Conditions
Interventions
Reduced-dose bevacizumab in combination with TACE and/or HAIC plus sintimab for the treatment of HCC patients:None
Standard-dose bevacizumab in combination with TACE and/or HAIC plus sintimab for the treatment of HCC patients:None
Sponsors
HenanCancerHospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years; 2. Confirmed diagnosis of hepatocellular carcinoma (HCC) based on imaging or pathological criteria; 3. Unresectable disease and having received at least one cycle of transcatheter arterial chemoembolization (TACE) and/or hepatic arterial infusion chemotherapy (HAIC) in combination with at least two cycles of sintilimab and a bevacizumab biosimilar; 4. At least one measurable lesion per RECIST version 1.1 criteria; 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; 6. Child-Pugh class A or B (score <= 7); 7. Barcelona Clinic Liver Cancer (BCLC) stage B or C; 8. Availability of complete baseline and follow-up data.
Exclusion criteria
Exclusion criteria: 1. Prior systemic or locoregional therapy for hepatocellular carcinoma; 2. Concurrent malignancy or history of other malignancies within the past 5 years; 3. Incomplete clinical data or loss to follow-up; 4. Subsequent receipt of surgical resection; 5. Non-standard or non-protocol-compliant treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Overall survival; | — |
Countries
China
Contacts
Public ContactHang Yuan
HenanCancerHospital
Outcome results
None listed